Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Histopathology. 2012 Jan;60(1):125-41. doi: 10.1111/j.1365-2559.2011.04083.x.
Prostate cancer is the most common malignant tumour in men and is a major research focus of pathologists, urologists and uro-oncologists alike. The pathologist is confronted with an increasing number of biospsies, necessitating ancillary tests in morphologically challenging cases. Next to basal cell markers, additional positive markers that aid in the differential diagnosis are presented here. The clinical decision of urologists, whom and how to treat these men, is dependent predominantly on pathological parameters, but still the grid spanned by these is too wide to allow a sufficient prognostication of the individual case. Here, a brief and critical overview is given of recent developments of prognostic biomarkers in prostate cancer.
前列腺癌是男性最常见的恶性肿瘤，也是病理学家、泌尿科医生和泌尿肿瘤学家共同关注的主要研究领域。病理学家面临着越来越多的活检，在形态学上具有挑战性的病例中需要辅助检查。除了基底细胞标志物外，本文还介绍了其他有助于鉴别诊断的阳性标志物。泌尿科医生的临床决策，即治疗这些男性的对象和方式，主要取决于病理参数，但这些参数的范围仍然太广，无法对个别病例进行充分的预后判断。在这里，简要而批判性地概述了前列腺癌中最近的预后生物标志物的发展。
